Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • COPD
  • Page 2
Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial
Posted inClinical Updates Respiratory Specialties

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

Posted by MedXY By MedXY 08/02/2025
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
Read More

Posts pagination

Previous page 1 2
  • Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes
  • Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight
  • FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease
  • Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes
  • Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in